HomeProductsBioactive CompoundsMetabolic EnzymesPDEZiritaxestat
Chemical structure of CAS 1628260-79-6

Ziritaxestat

CAS No.1628260-79-6
MDL No.MFCD31544330
MFC30H33FN8O2S
MW588.70
InChI KeyREQQVBGILUTQNN-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1628260-79-6
Product NameZiritaxestat

Biological Targets

ENPP2

Associated Conditions

idiopathic pulmonary fibrosis·fibrosis·systemic scleroderma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae.

Cancers • Vol. 12, Issue 2 • 2020
PMID: 32041123PMC: PMC7072337DOI: 10.3390/cancers12020374

Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer.

Molecular cancer therapeutics • Vol. 19, Issue 1 • 2020
PMID: 31548293DOI: 10.1158/1535-7163.MCT-19-0386

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

BMJ open respiratory research • Vol. 6, Issue 1 • 2019
PMID: 31179008PMC: PMC6530501DOI: 10.1136/bmjresp-2019-000422

Documentation

Similar Products